Zhonghua Gan Zang Bing Za Zhi. 2022 Aug 20;30(8):846-858. doi: 10.3760/cma.j.cn501113-20220622-00342.
In view of the high prevalence of diabetes mellitus in patients with liver cirrhosis and the increasing trend of non-alcoholic fatty liver disease-associated cirrhosis, the diagnosis and treatment of diabetes mellitus in patients with liver cirrhosis are becoming widespread concerns. Therefore, the Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association, organized multidisciplinary experts from gastroenterology, infective disease, endocrinology, etc, to draw up expert consensus on the management of diabetes mellitus in patients with liver cirrhosis, with focusing on the classification and management of hyperglycemia in cirrhotic patients. The consensus summarizes the prevalence, pathogenesis, clinical setting and prognosis of the concomitant diabetes mellitus in patients with liver cirrhosis, and definitely puts forward a proposal regarding "hepatogenous diabetes" as one of the four subtypes of diabetes mellitus in cirrhotic patients, and further recommends the basic principles for diagnosing and monitoring diabetes mellitus and the selection of antidiabetic drugs based on liver functions in patients with liver cirrhosis.
鉴于肝硬化患者中糖尿病的高患病率以及非酒精性脂肪性肝病相关肝硬化的上升趋势，肝硬化患者糖尿病的诊断和治疗正受到广泛关注。因此，中国医药生物技术协会慢性病管理分会组织了来自胃肠病学、传染病学、内分泌学等多学科专家，就肝硬化患者糖尿病的管理制定专家共识，重点关注肝硬化患者高血糖的分类和管理。该共识总结了肝硬化患者合并糖尿病的患病率、发病机制、临床情况及预后，并明确提出将“肝源性糖尿病”作为肝硬化患者糖尿病的四种亚型之一的提议，还进一步推荐了肝硬化患者糖尿病诊断和监测的基本原则以及基于肝功能的降糖药物选择。
